Tag

global company advancing

5 minuti di lettura

Novavax’s Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

(Adnkronos) – GAITHERSBURG, Md., Aug. 22, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that its updated protein-based XBB COVID vaccine

Immediapress

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

(Adnkronos) – GAITHERSBURG, Md., June 15, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, participated in today’s U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee’s

Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research

Immediapress

(Adnkronos) – GAITHERSBURG, Md., June 5, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has

Novavax’s Updated COVID-19 Vaccine Now Approved in the EU

Immediapress

(Adnkronos) – GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

martedì, 3 Ottobre 2023

Immediapress

(Adnkronos) – GAITHERSBURG, Md., Oct. 3, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

martedì, 3 Ottobre 2023

Immediapress

global company advancing

Novavax’s Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research

Novavax’s Updated COVID-19 Vaccine Now Approved in the EU

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

Primo piano

CdM approva decreto urgente per autotrasporto, agricoltura e pesca. Meloni: “Non tolleriamo intimidazioni” | Video

Il prete che ha mostrato il dito medio ai ragazzi durante i disordini a Milano: «Pentito? No, ho solo risposto»

Italia-Spagna, la sospensione di Schengen non sarà rinnovata

Blocco Tir, governo “sblocca” in Sicilia e Calabria, ma il Golfo di Napoli a rischio isolamento

Dopo gli scontri: cosa prevede il decreto e quali poteri hanno i militari

Sponsor

Suggerimenti

global company advancing

Primo piano

Sponsor